Hims & Hers CEO Disputes FTC's Understanding of Company Practices
On August 18, 2026, Hims & Hers Health (NYSE:HIMS) CEO Andrew Dudum told CNBC that the Federal Trade Commission’s lawsuit over data-sharing and subscription practices is based on a misunderstanding. He defended the company’s compounded GLP-1 drug sales as contributing to lower prices for weight-loss treatments. Despite regulatory challenges, Hims & Hers reported strong second-quarter revenue growth of nearly 40% year-over-year to $753 million, driven by over 300,000 new subscribers. The company raised its full-year revenue forecast and saw international revenue surge following the Eucalyptus acquisition. However, Hims & Hers faces financial pressures with a drop in adjusted gross margin from 76% to 64%, negative free cash flow of $68 million, and an overall net loss of $86.3 million due partly to legal costs and acquisitions.
Tickers: $HIMS
Topics: CEO statement data-sharing practices FTC lawsuit GLP-1 drugs revenue growth